EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion‐Dependent Thalassemia Identified Using Whole‐Genome Sequencing

Kittika Yampayon, Watchara Sakares iD, Krittin Pitinanon, Chanin Limwongse, Somdet Srichairatanakool, Pimpisid Koonyosying, Chonlaphat Sukasem, Kwankom Triparn, Jittima Piriyapongsa, Supachai Ekwattanakit, Vip Viprakasit iD, Varalee Yodsurang iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Kittika Yampayon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Deferasirox, Thalassemia, Iron Chelating Agents, Iron Overload. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Systems Research Institute, National Research Council of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deferasirox is a widely used oral iron chelator in patients with transfusion‐dependent thalassemia, but considerable variability in treatment response remains a clinical challenge. This study applied whole‐genome sequencing to investigate genetic predictors of deferasirox response in 88 Thai patients. This approach enabled comprehensive detection of both known and novel variants across eight key genes involved in deferasirox metabolism and transport. Two novel intronic variants in ABCC2 emerged as strong and clinically relevant predictors of treatment response. The homozygous TG deletion variant rs3047477 in ABCC2 (MAF 31.8%) was significantly associated with greater reductions in liver iron concentrations and increased iron excretion, whereas the rare variant rs188034361 was linked to poorer outcomes. Haplotype analysis identified a 69‐kilobase linkage block comprising 12 tightly linked variants, grouped into distinct clusters. Clusters 3.4 and 4.4 were associated with greater reductions in serum ferritin, whereas clusters 2.2, 2.3, and 4.5 predicted suboptimal response. Two variants in UGT1A3 were found to have novel associations with deferasirox response. Specifically, the rs33979061 variant (MAF 6.8%) was associated with poorer treatment outcomes, whereas the rs540607993 variant (MAF 1.1%) predicted enhanced ferritin reduction. Previously reported associations involving UGT1A1 (* 28 , * 6 ) and UGT1A3 (rs3806596) were also confirmed. Clinical factors, including baseline iron overload, transfusion intensity, body mass index, and age, also contributed to treatment variability. These findings support the implementation of pharmacogenetic profiling to guide personalized chelation strategies in patients with transfusion‐dependent thalassemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeferasiroxThalassemiaIron Chelating AgentsIron OverloadHumansFemaleMaleWhole Genome SequencingAdultMultidrug Resistance-Associated Protein 2Treatment OutcomeYoung AdultAdolescentChildATP-Binding Cassette, Sub-Family C ProteinsIronBlood TransfusionPolymorphism, Single NucleotideThailandGlucuronosyltransferasePharmacogenomic VariantsHaplotypes

Stichwörter der Autor:innen

drug transportefficacyenzymeshaplotypehematologypharmacogenomicspolymorphismprecision medicine

Substanzen

DeferasiroxMultidrug Resistance-Associated Protein 2Iron Chelating AgentsATP-Binding Cassette, Sub-Family C ProteinsIronGlucuronosyltransferaseABCC2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Siriraj Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Siriraj Genomics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Laboratory for Pharmacogenomics, Ramathibodi Hospital, Somdech Phra Debaratana Medical Center SDMC, Bangkok, Thailand.

ORCID-Profile: Watchara Sakares, Vip Viprakasit, Varalee Yodsurang

Förderung

  • Health Systems Research Institute
  • National Research Council of Thailand

Zitieren

APA

Yampayon, K., Sakares, W., Pitinanon, K., Limwongse, C., Srichairatanakool, S., Koonyosying, P., Sukasem, C., Triparn, K., Piriyapongsa, J., Ekwattanakit, S., Viprakasit, V., & Yodsurang, V. (2025). Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion‐Dependent Thalassemia Identified Using Whole‐Genome Sequencing. Clinical and Translational Science. https://doi.org/10.1111/cts.70441

Vancouver

Yampayon K, Sakares W, Pitinanon K, Limwongse C, Srichairatanakool S, Koonyosying P, et al. Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion‐Dependent Thalassemia Identified Using Whole‐Genome Sequencing. Clinical and Translational Science. 2025. doi:10.1111/cts.70441

BibTeX
@article{Yampayon2025,
  author = {Yampayon, Kittika and Sakares, Watchara and Pitinanon, Krittin and Limwongse, Chanin and Srichairatanakool, Somdet and Koonyosying, Pimpisid and Sukasem, Chonlaphat and Triparn, Kwankom and Piriyapongsa, Jittima and Ekwattanakit, Supachai and Viprakasit, Vip and Yodsurang, Varalee},
  title = {Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion‐Dependent Thalassemia Identified Using Whole‐Genome Sequencing},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70441}
}
Kostenlos starten →